abstract |
Bevacizumab for use in improving the overall survival of a patient suffering from cancer in which it is determined, from a sample of the patient, if the patient suffering from said cancer has the VEGFR-1 gene variant allele corresponding to rs9554316 (SEC ID No. 1), in which position 51 is G, and by means of which bevacizumab is administered to said patient having said variant allele of the VEGFR-1 gene. |